stephen barclay
stephen barclay
Consultant Hepatologist
Verified email at
Cited by
Cited by
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause‐specific outcomes
HA Innes, SA McDonald, JF Dillon, S Allen, PC Hayes, D Goldberg, ...
Hepatology 62 (2), 355-364, 2015
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
R Fan, G Papatheodoridis, J Sun, H Innes, H Toyoda, Q Xie, S Mo, ...
Journal of hepatology 73 (6), 1368-1378, 2020
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen
H Innes, ST Barclay, PC Hayes, A Fraser, JF Dillon, A Stanley, A Bathgate, ...
Journal of hepatology 68 (4), 646-654, 2018
Factors associated with spontaneous clearance of chronic hepatitis C virus infection
N Bulteel, PP Sarathy, E Forrest, AJ Stanley, H Innes, PR Mills, H Valerio, ...
Journal of hepatology 65 (2), 266-272, 2016
Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost‐effectiveness
HA Innes, SJ Hutchinson, S Barclay, E Cadzow, JF Dillon, A Fraser, ...
Hepatology 57 (2), 451-460, 2013
A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy
EJ Aspinall, W Mitchell, J Schofield, A Cairns, S Lamond, P Bramley, ...
Journal of viral hepatitis 23 (12), 1009-1016, 2016
Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a …
A Radley, M De Bruin, SK Inglis, PT Donnan, A Hapca, ST Barclay, ...
The lancet Gastroenterology & hepatology 5 (9), 809-818, 2020
Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population
H Innes, S McDonald, P Hayes, JF Dillon, S Allen, D Goldberg, PR Mills, ...
Journal of Hepatology 66 (1), 19-27, 2017
Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs
A Weir, A McLeod, H Innes, H Valerio, EJ Aspinall, DJ Goldberg, ...
Drug and alcohol dependence 165, 53-60, 2016
The management of chronic hepatitis B in the immunocompromised patient: recommendations from a single topic meeting
S Barclay, S Pol, D Mutimer, Y Benhamou, PR Mills, PC Hayes, ...
Journal of Clinical Virology 41 (4), 243-254, 2008
2014 UK consensus guidelines–hepatitis C management and direct‐acting anti‐viral therapy
MH Miller, K Agarwal, A Austin, A Brown, ST Barclay, P Dundas, ...
Alimentary pharmacology & therapeutics 39 (12), 1363-1375, 2014
Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland
G McAllister, H Innes, A Mcleod, JF Dillon, PC Hayes, R Fox, ST Barclay, ...
Journal of Clinical Virology 61 (3), 359-364, 2014
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs
HJ Cordell, JJ Fryett, K Ueno, R Darlay, Y Aiba, Y Hitomi, M Kawashima, ...
Journal of hepatology 75 (3), 572-581, 2021
Erratum to ‘The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting’[J. Clin. Virol. 41 (4) 2008 243–254]
S Barclay, S Pol, D Mutimer, Y Benhamou, PR Mills, PC Hayes, ...
Journal of Clinical Virology 42 (1), 104-115, 2008
Administration of end-of-life drugs by family caregivers during covid-19 pandemic
B Bowers, K Pollock, S Barclay
Bmj 369, 2020
Broad anti-hepatitis C virus (HCV) antibody responses are associated with improved clinical disease parameters in chronic HCV infection
RE Swann, VM Cowton, MW Robinson, SJ Cole, ST Barclay, PR Mills, ...
Journal of virology 90 (9), 4530-4543, 2016
End-of-life care during COVID-19: opportunities and challenges for community nursing
B Bowers, K Pollock, C Oldman, S Barclay
British journal of community nursing 26 (1), 44-46, 2021
Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial
GR Foster, K Agarwal, ME Cramp, S Moreea, S Barclay, J Collier, ...
Hepatology 67 (6), 2113-2126, 2018
Real‐world impact following initiation of interferon‐free hepatitis C regimens on liver‐related outcomes and all‐cause mortality among patients with compensated cirrhosis
SA McDonald, KG Pollock, ST Barclay, DJ Goldberg, A Bathgate, ...
Journal of viral hepatitis 27 (3), 270-280, 2020
Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale‐up of direct‐acting anti‐viral therapy in community …
NE Palmateer, A McAuley, JF Dillon, S McDonald, A Yeung, S Smith, ...
Addiction 116 (10), 2893-2907, 2021
The system can't perform the operation now. Try again later.
Articles 1–20